Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

The headline equity benchmarks ended with significant losses today, as investors turned cautious following the U.S. imposition of steep tariffs on multiple trade partners and the reaffirmation of a 25% import duty on Indian goods. Investors were also monitoring the ongoing earnings season. The Nifty settled below the 24,600 level after hitting the days high of 24,784.15 in mid-morning trade.

Barring the Nifty FMCG index, all the other sectoral indices on the NSE ended in red.

As per provisional closing data, the barometer index, the S&P BSE Sensex declined 585.67 points or 0.72% to 80,599.91. The Nifty 50 index lost 203 points or 0.82% to 24,565.35.

The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index slipped 1.37% and the S&P BSE Small-Cap index declined 1.59%.

The market breadth was weak. On the BSE, 1,307 shares rose and 2,711 shares fell. A total of 151 shares were unchanged.

The NSE’s India VIX, a gauge of the market’s expectation of volatility over the near term, rallied 3.74% to 11.98

Related Posts

Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

New Delhi: The Parliamentary Panel on Health and Family Welfare has recommended various significant regulatory changes in the regulation of medical devices, including decentralisation of approval for all medical devices…

Diabetic drug metformin found to act on brain

NEW DELHI:  Cheap, effective and widely trusted, metformin has long been the first choice for treating type 2 diabetes. Now, scientists say the drug works in a way few had…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

Diabetic drug metformin found to act on brain

Diabetic drug metformin found to act on brain

Hetero debuts semaglutide generic in emerging markets

Hetero debuts semaglutide generic in emerging markets

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

Stem cell therapy for autism illegal: NMC advisory

Stem cell therapy for autism illegal: NMC advisory